New data presented by Novartis Vaccines involving thousands of babies indicates that an investigational vaccine has the potential to be the first broad-coverage vaccine against the deadly meningococcal B (meningitis B) disease. 1 There is currently no broad-protection vaccine available against meningitis B, although vaccines exist against other strains. The findings were released at the International Pathogenic Neisseria Conference (IPNC) in Banff, Canada. The Phase III trial looked at a Multicomponent Meningococcal Serogroup B Vaccine (4CMenB)...
More...
More...